No abstract available
MeSH terms
-
Aminoglycosides / adverse effects
-
Animals
-
Anti-Bacterial Agents / adverse effects*
-
Antioxidants / pharmacology
-
Antioxidants / therapeutic use
-
Ciprofloxacin / pharmacology
-
Ciprofloxacin / therapeutic use
-
Female
-
Fluoroquinolones / adverse effects*
-
Fluoroquinolones / metabolism
-
Genetic Testing
-
Humans
-
Inactivation, Metabolic / genetics
-
Levofloxacin / adverse effects
-
Male
-
Mice
-
Mitochondria / drug effects
-
Mitochondria / pathology
-
Naphthyridines / adverse effects
-
Ofloxacin / adverse effects
-
Oxidative Stress / drug effects
-
Syndrome
-
Topoisomerase II Inhibitors / adverse effects
-
United States
-
United States Food and Drug Administration
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Antioxidants
-
Fluoroquinolones
-
Naphthyridines
-
Topoisomerase II Inhibitors
-
Ciprofloxacin
-
Levofloxacin
-
trovafloxacin
-
Ofloxacin